Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: OldBoar who wrote (1956)	5/21/2016 9:16:48 PM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

OB/RVL, one look at the vote totals and it is clear how Denner voted. Denner is not any smarter than the rest of us judging by his investments. He bet on both Apricus and Repros hoping that that one would succeed with their SERM (which would have been a blockbuster if it worked). Turns out SERMs were not a good bet, at least so far. However, Denner isn't going anywhere before the FDA decides on Vitaros. Letting Apricus go BK before that because it is a little short on cash would not be in his best interests. So I don't think you are missing anything. If the FDA approves Vitaros, you/we will be happy, particularly if you average at these prices. If the FDA does not approve Vitaros, then, well you know. The timeline that I see is the FDA making a decision no later than 3Q17 and maybe a little earlier if the review is faster because no additional clinical trials. James